 MINNEAPOLIS, MN ACCESSWIRE June 9, 2021 Celcuity Inc. NASDAQ:CELC, a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced the addition of two new senior executives to its clinical drug development and operations team. Igor Gorbatchevsky, MD, joined Celcuity as VP of Clinical Development and Jill Krause joined as VP of Clinical Operations. 